Works matching IS 09034641 AND DT 2024 AND VI 132 AND IP 10


Results: 8
    1
    2
    3
    4

    Real‐world data confirm elexacftor/tezacaftor/ivacaftor modulators halves sweat chloride concentration in eligible people with cystic fibrosis.

    Published in:
    APMIS, 2024, v. 132, n. 10, p. 728, doi. 10.1111/apm.13453
    By:
    • Bryrup, Thomas;
    • Faurholt‐Jepsen, Daniel;
    • Pressler, Tacjana;
    • Henriksen, Esben Herborg;
    • Leo‐Hansen, Christian;
    • Nielsen, Bibi Uhre;
    • Højte, Christine;
    • Mathiesen, Inger Hee Mabuza;
    • Katzenstein, Terese L.;
    • Jeppesen, Majbritt;
    • Jensen‐Fangel, Søren;
    • Olesen, Hanne Vebert;
    • Skov, Marianne;
    • Qvist, Tavs;
    • Olsen, Mette Frahm
    Publication type:
    Article
    5

    Peer‐to‐peer validation of Ki‐67 scoring in a pathology quality circle as a tool to assess interobserver variability: are we better than we thought?

    Published in:
    APMIS, 2024, v. 132, n. 10, p. 718, doi. 10.1111/apm.13451
    By:
    • Bernhardt, Marit;
    • Weinhold, Leonie;
    • Sanders, Christine;
    • Hommerding, Oliver;
    • Lau, Jan‐Frederic;
    • Toma, Marieta;
    • Tischler, Verena;
    • Schmid, Matthias;
    • Zienkiewicz, Tomasz;
    • Hildenbrand, Ralf;
    • Gerlach, Peter;
    • Zhou, Hui;
    • Braun, Martin;
    • Müller, Gunnar;
    • Sieber, Erich;
    • Marko, Christian;
    • Kristiansen, Glen
    Publication type:
    Article
    6
    7
    8

    Issue Information.

    Published in:
    APMIS, 2024, v. 132, n. 10, p. 673, doi. 10.1111/apm.13395
    Publication type:
    Article